Pyrazole compounds, formulations thereof, and a method for using the compounds and/or formulations
Lu Chou, Burlingame, CA (US); Matt Duan, Foster City, CA (US); Ihab S. Darwish, South San Francisco, CA (US); Simon Shaw, Oakland, CA (US); Somasekhar Bhamidipati, Foster City, CA (US); Vanessa Taylor, San Francisco, CA (US); Yan Chen, Foster City, CA (US); Dazhong Fan, South San Francisco, CA (US); and Zhushou Luo, South San Francisco, CA (US)
Assigned to Rigel Pharmaceuticals, Inc., South San Francisco, CA (US)
Filed by Rigel Pharmaceuticals, Inc., South San Francisco, CA (US)
Filed on Aug. 24, 2023, as Appl. No. 18/237,824.
Application 18/237,824 is a continuation of application No. 17/747,384, filed on May 18, 2022, abandoned.
Application 17/747,384 is a continuation of application No. 17/006,150, filed on Aug. 28, 2020, granted, now 11,370,787.
Claims priority of provisional application 62/894,547, filed on Aug. 30, 2019.
Prior Publication US 2023/0399326 A1, Dec. 14, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. C07D 417/14 (2006.01)
CPC C07D 417/14 (2013.01)
19 Claims
1. A compound that is sodium 1-(4-(4-((3-(3,6-difluoropyridin-2-yl)-1-((1r,4r)-4-ethoxycyclohexyl)-1H-pyrazol-4-yl) carbamoyl) thiazol-2-yl)-1H-pyrazol-1-yl)ethyl hydrogen phosphate.